Type-1 angiotensin II receptor A
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Type-1 angiotensin II receptor A as ChEMBL target CHEMBL329, mapped to UniProt P25095. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Type-1 angiotensin II receptor A matters
Type-1 angiotensin II receptor A is reviewed as Type-1 angiotensin II receptor A (UniProt P25095); the current evidence base includes 10 approved drugs, 267 compounds, and 30 assays, with lead potency reaching pChEMBL 9.6.
Type-1 angiotensin II receptor A Sequence length is 359 aa.
Review this target as Type-1 angiotensin II receptor A, mapped to UniProt P25095. Sequence length is 359 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 10 approved drugs, 267 compounds, and 30 assays for this target. The dominant activity type is EC50. CHEMBL1017 is the current potency anchor at pChEMBL 9.6.
Use CHEMBL1017 as the tractability anchor when discussing potency (pChEMBL 9.6).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Type-1 angiotensin II receptor A matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P25095, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1017
|
9.6 | Ki | Approved |
|
|
No preferred name
CHEMBL121
|
9.6 | Ki | Approved |
|
|
No preferred name
CHEMBL408403
|
9.4 | IC50 | Approved |
|
|
No preferred name
CHEMBL7550
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL7550
|
9.3 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ANGIOTENSIN II
CHEMBL408403
|
2017 |
|
|
ROSIGLITAZONE
CHEMBL121
|
1999 |
|
|
TELMISARTAN
CHEMBL1017
|
1998 |
|
|
IRBESARTAN
CHEMBL1513
|
1997 |
|
|
VALSARTAN
CHEMBL1069
|
1996 |
|
|
LOSARTAN
CHEMBL191
|
1995 |
|
|
SARALASIN
CHEMBL938
|
1982 |